Colin G Nichols Selected Research

KATP Channels

1/2022	ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm?
1/2022	ATP-sensitive potassium channels in zebrafish cardiac and vascular smooth muscle.
1/2021	Consequences of SUR2[A478V] Mutation in Skeletal Muscle of Murine Model of Cantu Syndrome.
1/2021	Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice.
1/2020	The Mechanism of High-Output Cardiac Hypertrophy Arising From Potassium Channel Gain-of-Function in Cantú Syndrome.
1/2020	Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity.
1/2020	Pathophysiological Consequences of KATP Channel Overactivity and Pharmacological Response to Glibenclamide in Skeletal Muscle of a Murine Model of Cantù Syndrome.
10/2019	ABCC9-related Intellectual disability Myopathy Syndrome is a KATP channelopathy with loss-of-function mutations in ABCC9.
1/2019	Pulmonary Hypertension and ATP-Sensitive Potassium Channels.
1/2018	Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Colin G Nichols Research Topics

Disease

10	Diabetes Mellitus 01/2022 - 05/2007
7	Type 2 Diabetes Mellitus (MODY) 01/2022 - 03/2004
6	Cantu syndrome 01/2021 - 11/2015
5	Hyperinsulinism (Hyperinsulinemia) 01/2022 - 10/2008
5	Hyperglycemia 01/2022 - 02/2009
4	Insulin Resistance 12/2018 - 07/2003
3	Intellectual Disability (Idiocy) 01/2022 - 11/2010
3	Channelopathies 10/2019 - 01/2017
3	Hypoglycemia (Reactive Hypoglycemia) 01/2019 - 06/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 10/2009
3	Cardiac Arrhythmias (Arrythmia) 08/2017 - 10/2009
3	Glucose Intolerance 01/2017 - 07/2003
3	Disease Progression 10/2011 - 02/2009
3	Epilepsy (Aura) 05/2010 - 02/2007
2	Muscular Diseases (Myopathy) 01/2022 - 10/2019
2	Congenital Hyperinsulinism 01/2022 - 01/2011
2	Atrophy 01/2021 - 01/2020
2	Cardiovascular Abnormalities 01/2020 - 11/2015
2	Hypertrophy 01/2020 - 01/2013
2	Pulmonary Hypertension 01/2019 - 01/2019
2	Ischemia 01/2018 - 03/2008
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2017 - 12/2012
2	Cystic Fibrosis (Mucoviscidosis) 01/2017 - 03/2015
2	Hypoxia (Hypoxemia) 11/2015 - 10/2008
2	Heart Failure 11/2014 - 09/2012
2	Seizures (Absence Seizure) 12/2012 - 11/2010
2	Hypersensitivity (Allergy) 10/2011 - 01/2011
2	Infarction (Infarctions) 08/2011 - 03/2008
2	Myocardial Ischemia (Ischemic Heart Diseases) 02/2009 - 03/2008
2	Reperfusion Injury 02/2009 - 03/2008
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 10/2022
1	Lymphedema (Milroy Disease) 10/2022
1	Edema (Dropsy) 01/2021
1	Cardiomegaly (Heart Hypertrophy) 01/2020
1	Pathologic Processes 01/2019
1	Critical Illness (Critically Ill) 01/2019
1	Inflammation (Inflammations) 12/2018
1	Congenital Heart Defects (Congenital Heart Defect) 01/2018
1	Malaria 12/2016
1	Glioma (Gliomas) 04/2016
1	Heart Diseases (Heart Disease) 01/2016
1	Chronic Obstructive Pulmonary Disease (COPD) 03/2015
1	Asthma (Bronchial Asthma) 03/2015
1	Neoplasms (Cancer) 03/2015
1	Pathologic Complete Response 11/2014
1	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2013
1	Ventricular Remodeling 01/2013
1	Uniparental Disomy 01/2011
1	SeSAME syndrome 11/2010
1	Hearing Loss (Hearing Impairment) 11/2010
1	Ataxia (Dyssynergia) 11/2010
1	Diabetic Cardiomyopathies 02/2010
1	Developmental Delay, Epilepsy, and Neonatal Diabetes 02/2007
1	Permanent Neonatal Diabetes Mellitus 02/2007
1	Type 2 Maturity-Onset Diabetes of the Young 10/2005

Drug/Important Bio-Agent (IBA)

25	Adenosine Triphosphate (ATP)IBA 10/2022 - 03/2004
22	KATP ChannelsIBA 01/2022 - 03/2008
11	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 07/2003
10	Insulin (Novolin)FDA Link 12/2020 - 12/2004
7	PotassiumIBA 01/2021 - 03/2004
5	Glyburide (Glibenclamide)FDA LinkGeneric 01/2020 - 02/2009
3	Proteins (Proteins, Gene)FDA Link 12/2016 - 12/2009
3	Sulfonylurea ReceptorsIBA 02/2009 - 05/2007
2	Dihydroxyphenylalanine (Dopa)IBA 11/2014 - 01/2011
2	Diazoxide (Hyperstat)FDA Link 06/2014 - 08/2011
1	Messenger RNA (mRNA)IBA 01/2021
1	Polymethyl Methacrylate (Sol)IBA 01/2020
1	Potassium Channels (Potassium Channel)IBA 01/2020
1	Sildenafil Citrate (Viagra)FDA Link 01/2019
1	SolutionsIBA 01/2018
1	Acetaminophen (Paracetamol)FDA LinkGeneric 01/2018
1	Alprostadil (Muse)FDA LinkGeneric 01/2018
1	Ibuprofen (Motrin)FDA LinkGeneric 01/2018
1	Indomethacin (Indometacin)FDA LinkGeneric 01/2018
1	Krebs-Henseleit solutionIBA 01/2018
1	Glipizide (Glucotrol)FDA LinkGeneric 12/2017
1	C-PeptideIBA 12/2017
1	Ion Channels (Ion Channel)IBA 08/2017
1	ChloridesIBA 01/2017
1	Kcnj10 (channel)IBA 04/2016
1	AnoctaminsIBA 03/2015
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2013
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2013
1	Doxycycline (Periostat)FDA LinkGeneric 01/2013
1	DNA (Deoxyribonucleic Acid)IBA 12/2012
1	AutoantibodiesIBA 12/2012
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 09/2012
1	NucleotidesIBA 03/2012
1	Blood Glucose (Blood Sugar)IBA 10/2011
1	SaltsIBA 11/2010
1	Protein Isoforms (Isoforms)IBA 05/2010
1	Fatty Acids (Saturated Fatty Acids)IBA 02/2010
1	Tamoxifen FDA LinkGeneric 02/2009
1	Pharmaceutical PreparationsIBA 10/2008
1	Hypoglycemic Agents (Hypoglycemics)IBA 10/2008
1	GlucokinaseIBA 10/2005
1	EstersIBA 03/2004
1	Hormones (Hormone)IBA 03/2004

Therapy/Procedure

3	Therapeutics 01/2019 - 10/2012
1	Glycemic Control 02/2009